Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
بقلم هيئة تحرير كرونيكل · · المصدر: TechCrunch
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are
المزيد من كرونيكل
- New 10p coin enters circulation - will you spot one?
- Kit Harington joins HBO's Harry Potter series as Gilderoy Lockhart
- Palmer shines as Chelsea secure narrow victory over Fulham
- Al-Hilal nearing deal to acquire Arsenal's Gabriel Martinelli
- Rogers & Palmer star but Sanchez struggles - Fulham v Chelsea player ratings
- Man City linked with Gakpo as transfer rumors swirl
- Zillow, Redfin Resolve FTC Dispute Over Rental Ad Practices
- England's World Cup Dream Dashed by Netherlands Stalemate
- Reserve Your Startup Exhibit Spot at TechCrunch Disrupt 2026
- Hodgkinson withdraws from Zurich Diamond League
- Alabama launches investigation into OpenAI’s hack of Hugging Face
- Manga-inspired theme park to be built near Paris